Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
13/10/2026 21:32
BRIEF-Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases Generate Biomedicines Inc GENB.O:
GENERATE BIOMEDICINES AND ZEALAND PHARMA ENTER COLLABORATION AND LICENSE AGREEMENT TO DEVELOP PROTEIN THERAPEUTICS ENGINEERED WITH AI FOR METABOLIC DISEASES
GENERATE BIOMEDICINES - TO RECEIVE $30 MILLION UPFRONT, UP TO $1.20 BILLION IN MILESTONES, PLUS ROYALTIES
GENERATE BIOMEDICINES - COLLABORATION TO DEVELOP MULTISPECIFIC PROTEIN THERAPEUTICS FOR OBESITY AND METABOLIC DISEASES
GENERATE BIOMEDICINES - TO LEAD RESEARCH; ZEALAND PHARMA TO HANDLE CLINICAL DEVELOPMENT AND COMMERCIALIZATION
GENERATE BIOMEDICINES - CO TO LEAD RESEARCH; ZEALAND PHARMA TO HANDLE CLINICAL DEVELOPMENT AND COMMERCIALIZATION
Source text: ID:nGNX9WNXY0
Further company coverage: GENB.O
Recent news on Generate Biomedicines
See all newsZealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)
Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Brief: Zealand Pharma Makes Deal With Generate Worth Up To $1.2 Billion - Bloomberg News
Brief: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer